Read Trending Stories
- » Healthcare Biz Recap: Rosetta Genomics Spikes, Dynasil Pops, J&J Ticks Up
- » Traders Fret Over Direction: Europe's Woes and a Faceplant Bloom
- » Rearview Snapshot: Apple Rejects U.S. Govt, HP Shines, Oil Rebounds
- » Tech Biz Recap: H-P's Earnings Reaction, Facebook's New App
- » Late Radar: BlackRock Ups CHK Stake, VeriFone Crashes 9%
Today's Trending Stocks
Click a Company to Research Now:
- Bank of America (BAC)
- Apple . (AAPL)
- Facebook (FB)
- AT&T (T)
- Nokia (NOK)
- Tiffany & Co. (TIF)
- Signet Jewelers Ltd. (SIG)
- NetApp . (NTAP)
Apple Inc. (NASDAQ:AAPL): Piper Jaffray continues to believe Apple is preparing to launch a television after speaking to a major TV component supplier who was contacted by Apple regarding various capabilities of their television display components. Piper said it is confident that Apple will enter the connected TV market, but notes the timing remains uncertain. The firm thinks a television launch target is likely in late 2012 and keeps an Overweight rating on Apple shares.
Amazon.com Inc. (NASDAQ:AMZN): Collins Stewart attributes Amazon.com’s Q4 revenue miss to accelerated mix shift to third party units, but notes the company’s paid units growth remains strong. The firm continues to believe Amazon will likely gain substantial share of online and offline retail while aggressively investing in fulfillment capacity, which will hurt margins. Collins lowered its price target for Amazon shares and reiterates a Neutral rating on the stock.
U.S. Bancorp (NYSE:USB): U.S. Bancorp added to Key Call list at UBS.
ViroPharma Inc.(NASDAQ:VPHM): After ordering Form 483s for the recent FDA inspections of both Cinryze plants, Jefferies believes manufacturing issues remain outstanding that could prevent FDA approval of Cinryze expanded manufacturing, which is expected within the next week. However, the firm says a complete response letter would only be a minor setback, and keeps a Buy rating on ViroPharma shares.
Cytec Industries Inc.(NYSE:CYT): Credit Suisse said Cytec reported a blowout Q4 with implied guidance above the Street. The firm rates Cytec an Outperform with a $65 price target, up from $60.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com
To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com
Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!


